For example, even despite encouraging early results from the Keynote-001 trail suggesting potential efficacy of pembrolizumab in TKI-naïve EGFR-mutated NSCLC, these were invalidated in a subsequent phase 2 trial [4, 5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.